|
Deferred Research And Development Arrangement (Details) (USD $)
|
3 Months Ended | 9 Months Ended | 12 Months Ended | 3 Months Ended | 9 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2013
|
Dec. 31, 2012
|
Sep. 30, 2013
Rexgene [Member]
|
Sep. 30, 2012
Rexgene [Member]
|
Sep. 30, 2013
Rexgene [Member]
|
Sep. 30, 2012
Rexgene [Member]
|
Dec. 31, 2003
Rexgene [Member]
|
Dec. 31, 2012
Rexgene [Member]
|
Sep. 30, 2013
Teva Pharmaceutical Industries, Ltd. [Member]
|
Sep. 30, 2013
Teva Pharmaceutical Industries, Ltd. [Member]
|
Dec. 31, 2012
Teva Pharmaceutical Industries, Ltd. [Member]
|
Nov. 27, 2012
Teva Pharmaceutical Industries, Ltd. [Member]
|
|
| Research and development arrangement, one-time fee | $ 1,500,000 | |||||||||||
| Reduction of research and development expenses | 18,750 | 18,750 | 56,250 | 56,250 | 59,700 | 404,321 | ||||||
| Deferred Research and Development Arrangement | 1,165,429 | 1,626,000 | 693,750 | 693,750 | 750,000 | 471,679 | 471,679 | 876,000 | ||||
| Royalties paid, percentage of net sales | 3.00% | |||||||||||
| Restricted Cash and Cash Equivalents, Noncurrent | $ 509,179 | $ 1,091,801 | $ 926,000 | |||||||||